Investment Analysts’ Weekly Ratings Updates for aTyr Pharma (ATYR)

aTyr Pharma (NASDAQ: ATYR) recently received a number of ratings updates from brokerages and research firms:

  • 11/14/2026 – aTyr Pharma was downgraded by Wall Street Zen from “hold” to “strong sell”.
  • 11/6/2026 – aTyr Pharma was downgraded by Freedom Broker from “strong-buy” to “hold”.
  • 11/6/2026 – aTyr Pharma had its price target lowered by Royal Bank Of Canada to $6.00. They now have a “sector perform” rating on the stock.
  • 11/6/2026 – aTyr Pharma had its price target raised by Wells Fargo & Company from $1.00 to $4.00. They now have an “equal weight” rating on the stock.
  • 10/31/2026 – aTyr Pharma was upgraded by Wall Street Zen to “hold”.

aTyr Pharma Price Performance

Shares of aTyr Pharma stock opened at $5.24 on Tuesday. The company has a market cap of $13.36 million, a PE ratio of -0.24 and a beta of 1.04. The firm has a fifty day moving average price of $10.03 and a two-hundred day moving average price of $22.93. aTyr Pharma, Inc. has a fifty-two week low of $4.07 and a fifty-two week high of $44.40.

aTyr Pharma (NASDAQ:ATYR – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported ($7.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.00) by ($3.43). Analysts expect that aTyr Pharma, Inc. will post -22.96 earnings per share for the current fiscal year.

aTyr Pharma is a clinical-stage biotechnology company focused on developing medicines based on the extracellular biology of tRNA synthetases, a family of proteins involved in cellular processes. The company is headquartered in San Diego, California. Its lead drug candidate, efzofitimod, is an immunomodulator being studied for pulmonary sarcoidosis and other interstitial lung diseases. The candidate is designed to act through neuropilin-2, a receptor involved in immune regulation. aTyr’s research programs draw on its work in tRNA synthetase biology, with the broader goal of developing treatments for inflammatory and fibrotic conditions.

Read More

Receive News & Ratings for aTyr Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.